Why did Globe Life (GL) stock move recently?

On 7/23/2026, Globe Life moved -7.0% — Globe Life shares fell after its Q2 2026 net operating EPS of $3.61 missed consensus estimates (by ~1.6%) amid higher expenses, outweighing revenue/premium growth and a raised full-year 2026 EPS guidance range of $15.55-15.95. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Globe Life (GL) overvalued or fairly valued?

MarketChacha shows Globe Life's valuation in context — a trailing P/E of about 12.4, a forward P/E of about 11.1, a price-to-book of about 2.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Globe Life's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.34×) from reported figures — education, not a rating.

What is Globe Life's revenue?

Globe Life reported revenue of $6.0B for FY2025, with net profit of $1.2B, per official filings.

What is the share price of Globe Life (GL)?

Globe Life last traded at $183.26 (-0.3% on the day), as of 8/10/2026 — a delayed quote shown for education, not investment advice.

Globe Life

GL · NYSE · Financials · United States

Snapshot

TickerGL

ExchangeNYSE

SectorFinancials

IndustryInsurance - Life

CountryUnited States

Employees3,695

HeadquartersMcKinney, United States

Websitehome.globelifeinsurance.com

Filings tracked15

About Globe Life

Globe Life Inc., through its subsidiaries, provides various life and supplemental health insurance products to lower middle- and middle-income families in the United States. It operates in three segments: Life Insurance, Supplemental Health Insurance, and Investments. The company offers whole, term, and other life insurance products, as well as life insurance for children; Medicare supplement and limited-benefit supplemental health insurance products, such as accident, cancer, critical illness, heart, intensive care, and other health products; and final expense, accidental death, mortgage protection, and hospital insurance products. It sells its products through direct-to-consumer channels, exclusive independent agents, general agency independent agents, and brokers. The company was formerly known as Torchmark Corporation and changed its name to Globe Life Inc. in August 2019. Globe Life Inc. was founded in 1900 and is headquartered in McKinney, Texas.

Who owns it

Insiders0.7%
Institutions87.9%
Public & other11.4%

974 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.7.19%
Vanguard Capital Management LLC6.70%
Vanguard Portfolio Management LLC5.54%
Invesco Ltd.5.23%
State Street Corporation4.86%
Geode Capital Management, LLC3.55%
Dimensional Fund Advisors LP3.06%
Morgan Stanley2.51%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.34×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend17.8% → 19.4%

Margin has expanded by about 1.6 points — the business is getting more profitable.

Return on equity19.4%

Latest ROE of 19.4% — capital is generating a healthy return.

Growth qualityrev 5% · PAT 9%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $1.6B · EPS 3.79

Est. earnings growth +11.7%

Next fiscal year

Rev $6.8B · EPS 16.52

Est. earnings growth +5.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$6.0B

Net margin

19.4%

ROE

19.4%

Revenue CAGR (2y)

+4.9%

Profit CAGR (2y)

+9.4%

EPS (FY2025)

14.07

Net profit (FY2025)

$1.2B

Ask MarketChacha about GL

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 23, 2026
Globe Life shares fell after its Q2 2026 net operating EPS of $3.61 missed consensus estimates (by ~1.6%) amid higher expenses, outweighing revenue/premium growth and a raised full-year 2026 EPS guidance range of $15.55-15.95.
source 1 ↗source 2 ↗source 3 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$6.0B	$1.2B	14.07	19.4%	19.4%
FY2024	$5.8B	$1.1B	11.94	18.5%	20.2%
FY2023	$5.4B	$970.8M	10.07	17.8%	21.6%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$1.6B	$287.7M	3.65	18.0%
2026Q1	$1.6B	$270.5M	3.39	17.3%
2025Q3	$1.5B	$387.8M	4.73	25.6%
2025Q2	$1.5B	$252.7M	3.05	17.1%
2025Q1	$1.5B	$254.6M	3.01	17.2%
2024Q3	$1.5B	$303.0M	3.44	20.8%
2024Q2	$1.4B	$258.4M	2.83	17.9%
2024Q1	$1.4B	$254.2M	2.67	18.0%
2023Q4	$1.4B	$274.8M	2.88	19.4%
2023Q3	$1.4B	$257.1M	2.68	18.6%
2023Q2	$1.3B	$215.3M	2.24	16.2%
2023Q1	$1.3B	$223.6M	2.28	16.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change
SEC8/7/2026material
10-Q — 10-Q (Q2 2026)
SEC8/5/2026
8-K — Results of operations, Exhibits
SEC7/22/2026material
8-K — Material agreement, Exhibits
SEC6/29/2026material
10-Q — 10-Q (Q1 2026)
SEC5/7/2026
8-K — Executive/director change, Shareholder vote results
SEC5/4/2026material
8-K — Results of operations, Exhibits
SEC4/22/2026material
8-K — Executive/director change
SEC2/27/2026material
10-K filing
SEC2/25/2026
8-K — Results of operations, Exhibits
SEC2/4/2026material

2025

8-K — Executive/director change, Exhibits
SEC11/6/2025material
10-Q — 10-Q (Q3 2025)
SEC11/5/2025
8-K — Results of operations, Exhibits
SEC10/22/2025material
10-Q — 10-Q (Q2 2025)
SEC8/6/2025
8-K — Other events, Exhibits
SEC7/29/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.